Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eagle Bags Vasopressin Exclusivity And Details Launch Plans

US Agency Also Dishes Out Tentative Nod For Amphastar’s’ ANDA Product

Executive Summary

Generic competition to Vasostrict is nearing in the US after the FDA confirmed Eagle’s previously unresolved potential for 180-day market exclusivity.

You may also be interested in...



Primatene Mist Drives Amphastar Sales Growth

Amphastar reported double-digit growth in the fourth quarter driven by sales of Primatene Mist, epinephrine products and glucagon. The company also revealed that it is anticipating a Q3 FY22 launch of vasopressin.

Amphastar Grows With Primatene Mist, Epinephrine And Glucagon

Amphastar has reported double-digit growth in the fourth quarter of 2021, as the company sees sales growth from Primatene Mist, epinephrine products and glucagon. The company also revealed that it is anticipating a Q3 FY22 launch of vasopressin.

Endo Sweats On Vasostrict Competition While Varenicline Is A Boon

Endo management turned talk once again to its expectations for Vasostrict competition in the coming months during its year-end earnings call. The US-based firm enjoyed a better end to the year as it capitalized on the opportunity for shortage-hit varenicline.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel